Strategies for next generation anti-CTLA-4 antibodies included non-fucosylated ipilimumab for enhanced activity via increased FcγR binding and a ProbodyTM version of anti-CTLA-4 for improved safety that localizes the drug activity to the tumor. The gene discussed is CTLA4; the disease is neoplasm.